CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The XEND project focuses on developing XEN-D0501, a new oral medication targeting Type 2 diabetes by inhibiting the TRPV1 receptor. This innovative approach aims to improve treatment options and quality of life for the growing number of diabetes patients worldwide.
The XEND project aims to take key steps towards establishing a transient receptor potential vanilloid (TRPV1) antagonist, XEN-D0501, as a novel oral treatment for Type 2 diabetes (T2D).
Diabetes is a constantly growing global epidemic.
According to recent estimation, 422 million people worldwide are affected by the disease with a prevalence rate of 8.3%, and 46.3% still remains undiagnosed.Due to high risks of complications and related problems from mismanagement, closely controlling the treatme…
PILA PHARMA AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
